Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Neuphoria Therapeutics Inc. (NEUP) had Stock-Based Compensation of $0.07M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$15.00M |
|
$11.26M |
|
-- |
|
$15.00M |
|
$3.02M |
|
$11.98M |
|
$-0.80M |
|
$11.18M |
|
$11.18M |
|
$11.26M |
|
$11.26M |
|
$11.26M |
|
$11.26M |
|
$11.98M |
|
$12.14M |
|
1.72M |
|
1.72M |
|
$6.55 |
|
$6.55 |
|
| Balance Sheet Financials | |
$17.09M |
|
$0.00M |
|
$13.62M |
|
$30.71M |
|
$1.55M |
|
-- |
|
$3.16M |
|
$4.72M |
|
$26.00M |
|
$12.58M |
|
$26.00M |
|
1.85M |
|
| Cash Flow Statement Financials | |
$3.66M |
|
-- |
|
$0.82M |
|
$12.69M |
|
$17.12M |
|
$4.43M |
|
|
Stock-Based Compensation |
$0.07M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
79.85% |
|
79.85% |
|
-- |
|
74.54% |
|
75.08% |
|
$3.66M |
|
-- |
|
-- |
|
-- |
|
0.49 |
|
-- |
|
609.95 |
|
0.15 |
|
43.32% |
|
89.55% |
|
36.67% |
|
43.32% |
|
$14.02 |
|
$2.13 |
|
$2.13 |
|